These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32128700)

  • 1. Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission.
    Asami Y; Pan J; Oh M; Sato A
    Ther Innov Regul Sci; 2020 Sep; 54(5):1134-1137. PubMed ID: 32128700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
    Yang H; Novick S; Burdick RK
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Japanese regulation of biosimilar products: past experience and current challenges.
    Arato T
    Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical considerations regarding correlated lots in analytical biosimilar equivalence test.
    Shen M; Wang T; Tsong Y
    J Biopharm Stat; 2017; 27(2):213-219. PubMed ID: 27906604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Consistency Test.
    Pan Z; Huang W; Pan J; Koch G
    Ther Innov Regul Sci; 2021 Jul; 55(4):765-772. PubMed ID: 33797059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
    Rivera VM
    Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
    Fleischmann RM; Alten R; Pileckyte M; Lobello K; Hua SY; Cronenberger C; Alvarez D; Bock AE; Sewell KL
    Arthritis Res Ther; 2018 Aug; 20(1):178. PubMed ID: 30111357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
    Dong XC; Weng YT; Tsong Y
    J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins.
    Li Y; Liu Q; Wood P; Johri A
    Stat Med; 2013 Feb; 32(3):393-405. PubMed ID: 22991275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
    Kim WS; Buske C; Ogura M; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Osmanov D; Kwak LW; Lee SJ; Lee SY; Bae YJ; Coiffier B
    Lancet Haematol; 2017 Aug; 4(8):e362-e373. PubMed ID: 28712940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha.
    Barakhoeva Z; Vovk L; Fetisova Y; Marilova N; Ovchinnikova M; Tischenko M; Scherbatyuk Y; Kolotovkina A; Miskun A; Kasyanova G; Teterina T; Zorina I; Belousova N; Morozova E; Yakovenko S; Apryshko V; Sichinava L; Shalinа R; Polzikov M
    Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():6-12. PubMed ID: 31400644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.